Buglioni S - Search Results

1

Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.

Scalera S, Ricciuti B, Mazzotta M, Calonaci N, Alessi JV, Cipriani L, Bon G, Messina B, Lamberti G, Di Federico A, Pecci F, Milite S, Krasniqi E, Barba M, Vici P, Vecchione A, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Buglioni S, Pescarmona E, Sharma B, Felt KD, Lindsay J, Rodig SJ, De Maria R, Caravagna G, Cappuzzo F, Ciliberto G, Awad MM, Maugeri-Saccà M. Scalera S, et al. Among authors: buglioni s. Ann Oncol. 2023 Mar;34(3):275-288. doi: 10.1016/j.annonc.2022.12.002. Epub 2022 Dec 13. Ann Oncol. 2023. PMID: 36526124 Free article.

2

Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.

Prieto-Potin I, Montagut C, Bellosillo B, Evans M, Smith M, Melchior L, Reiltin W, Bennett M, Pennati V, Castiglione F, Bürrig KF, Cooper U, Dockhorn-Dworniczak B, Rossenbach C, Luna-Aguirre CM, Barrera-Saldaña HA, Machado JC, Costa JL, Yacobi R, Tabibian-Keissar H, Buglioni S, Ronchetti L, Douglas-Berger L, Dubbink HJ, Alorini M, Sabourin JC, Rojo F. Prieto-Potin I, et al. Among authors: buglioni s. J Mol Diagn. 2018 Sep;20(5):664-676. doi: 10.1016/j.jmoldx.2018.05.008. Epub 2018 Jun 26. J Mol Diagn. 2018. PMID: 29959022 Free article.

3

Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase.

Di Filippo F, Di Filippo S, Ferrari AM, Antonetti R, Battaglia A, Becherini F, Bernet L, Boldorini R, Bouteille C, Buglioni S, Burelli P, Cano R, Canzonieri V, Chiodera P, Cirilli A, Coppola L, Drago S, Di Tommaso L, Fenaroli P, Franchini R, Gianatti A, Giannarelli D, Giardina C, Godey F, Grassi MM, Grassi GB, Laws S, Massarut S, Naccarato G, Natalicchio MI, Orefice S, Palmieri F, Perin T, Roncella M, Roncalli MG, Rulli A, Sidoni A, Tinterri C, Truglia MC, Sperduti I. Di Filippo F, et al. Among authors: buglioni s. J Exp Clin Cancer Res. 2016 Dec 8;35(1):193. doi: 10.1186/s13046-016-0460-6. J Exp Clin Cancer Res. 2016. PMID: 27931238 Free PMC article.

4

USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer.

Rossi FA, Enriqué Steinberg JH, Calvo Roitberg EH, Joshi MU, Pandey A, Abba MC, Dufrusine B, Buglioni S, De Laurenzi V, Sala G, Lattanzio R, Espinosa JM, Rossi M. Rossi FA, et al. Among authors: buglioni s. Oncogenesis. 2021 Mar 13;10(3):28. doi: 10.1038/s41389-021-00318-x. Oncogenesis. 2021. PMID: 33714979 Free PMC article.

5

c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings.

Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, Ricciotti A, Citro G, Cosimelli M, Ramsay RG, Calabretta B, Zupi G. Biroccio A, et al. Among authors: buglioni s. Am J Pathol. 2001 Apr;158(4):1289-99. doi: 10.1016/S0002-9440(10)64080-1. Am J Pathol. 2001. PMID: 11290547 Free PMC article.

6

PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.

Lattanzio R, Iezzi M, Sala G, Tinari N, Falasca M, Alberti S, Buglioni S, Mottolese M, Perracchio L, Natali PG, Piantelli M. Lattanzio R, et al. Among authors: buglioni s. BMC Cancer. 2019 Jul 30;19(1):747. doi: 10.1186/s12885-019-5949-x. BMC Cancer. 2019. PMID: 31362705 Free PMC article.

7

Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity.

Zaffaroni N, Della Porta C, Villa R, Botti C, Buglioni S, Mottolese M, Grazia Daidone M. Zaffaroni N, et al. Among authors: buglioni s. J Pathol. 2002 Sep;198(1):37-46. doi: 10.1002/path.1178. J Pathol. 2002. PMID: 12210061

8

The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity.

Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, Noonan DM, Natali PG, Albini A. Morini M, et al. Among authors: buglioni s. Int J Cancer. 2000 Aug 1;87(3):336-42. Int J Cancer. 2000. PMID: 10897037 Free article.

9

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

Mottolese M, Benevolo M, Del Monte G, Buglioni S, Papaldo P, Nisticò C, Di Filippo F, Vasselli S, Vici P, Botti C. Mottolese M, et al. Among authors: buglioni s. J Cancer Res Clin Oncol. 2000 Dec;126(12):722-9. doi: 10.1007/pl00008478. J Cancer Res Clin Oncol. 2000. PMID: 11153146

10

Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.

Botti C, Buglioni S, Benevolo M, Giannarelli D, Papaldo P, Cognetti F, Vici P, Di Filippo F, Del Nonno F, Venanzi FM, Natali PG, Mottolese M. Botti C, et al. Among authors: buglioni s. Clin Cancer Res. 2004 Feb 15;10(4):1360-5. doi: 10.1158/1078-0432.ccr-1092-03. Clin Cancer Res. 2004. PMID: 14977837

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page